Introduction
============

This issue of *Frontiers in Immunologic Tolerance* explores barriers to tolerance from a variety of views of cells, molecules, and processes of the immune system. Our laboratory has spent over a decade focused on the migration of the cells of the immune system, and dissecting the signals that determine how and where effector and suppressive regulatory T cells traffic from one site to another in order to reject or protect allografts. These studies have led us to a greater appreciation of the anatomic structure of the immune system, and the realization that the path taken by lymphocytes during the course of the immune response to implanted organs determines the final outcome. In particular, the structures, microanatomic domains, and the cells and molecules that lymphocytes encounter during their transit through blood, tissues, lymphatics, and secondary lymphoid organs (SLOs) are powerful determinants for whether tolerance is achieved. Thus, the understanding of complex cellular and molecular processes of tolerance will not come from "96-well plate immunology," but from an integrated understanding of the temporal and spatial changes that occur during the response to the allograft. The study of the precise positioning and movement of cells in lymphoid organs has been difficult since it is hard to visualize cells within their three-dimensional setting; instead techniques have tended to be dominated by two-dimensional renderings, although advanced confocal and two-photon systems are changing this view. It is difficult to precisely modify key molecules and events in lymphoid organs, so that existing knockouts, transgenics, inhibitors, and activators have global and pleiotropic effects, rather than precise anatomically restricted influences. Lastly, there are no well-defined postal codes or tracking systems for leukocytes, so that while we can usually track cells from point A to point B, it is exponentially more difficult or even impossible to track them to point C and beyond. We believe this represents one of the fundamental barriers to understanding the immune system and devising therapeutic approaches that take into account anatomy and structure as major controlling principles of tolerance.

Secondary Lymphoid Organs
=========================

Structure
---------

It is first important to understand the structure, development, and regulatory mechanisms of lymphoid organs to provide the basis for understanding on how these control immunity and tolerance. The lymph node (LN) is an encapsulated, highly organized SLO (Figures [1](#F1){ref-type="fig"}C,D). The separate regions are the cortex, the paracortex, and the medulla. The cortex is the most outer layer and contains B cells, macrophages, and follicular dendritic cells (FDC) arranged in primary follicles. The paracortex is the next layer, which contains T cells and dendritic cells (DC). Fibroblastic reticular cells (FRC) support T cell and DC interactions in this area. The most inner layer, the medulla, consists of lymphatic tissues called medullary cords, which are separated by the lymph filled spaces of the medullary sinuses. The LN vasculature consists of high endothelial venules (HEV), the characteristic structure through which T cells and B cells enter into LN from the blood, and lymphatic vessels lined by lymphatic endothelial cells (LEC).

![**Structure of SLO. Fluorescent immunohistochemistry (left) and cartoons (right) illustrate the structure and cellular content of spleen (A,B) and LN (C,D)**. **(A)** The outer capsule of the spleen surrounds the red pulp, with the sinuses and white pulp embedded within. ER-TR7 fibers form a network supporting the red pulp, and FRC line the borders between the red and white pulp. A central arteriole empties into the white pulp. **(B)** In the white pulp, T cells populate the PALS leading into the B cell follicles. DC line the marginal sinus, enclosed by the marginal zone. **(C)** In the LN, the efferent lymphatics empty into the medullary sinus and travel through the medullary cords. Lymphocytes enter through the HEV, which seed the LN. **(D)** B cells, FDC, and macrophages lay in the cortex. The paracortex contains T cells and DC. Antigen presentation and T cell priming occur at the cortical ridge areas between B and T cell zones supported by FRC.](fimmu-02-00064-g001){#F1}

The spleen is surrounded by a capsule that extends many projections into the interior to form a compartmentalized structure (Figures [1](#F1){ref-type="fig"}A,B). There are two compartments, the red pulp and the white pulp, and a diffuse marginal zone that separates them. The red pulp is a network of sinusoids populated by macrophages and red blood cells. The splenic white pulp forms a periarteriolar lymphoid sheath (PALS) populated mainly by T cells. B cell follicles, supported by FDC as in the LN, are next to the PALS. The marginal sinus and its associated layer of FRC and MOMA-1 staining metallophilic macrophages define the outer boundary of the white pulp.

LTi and LTo cells -- definition and function
--------------------------------------------

Lymph nodes develop during embryogenesis or in the first few weeks after birth through recruitment and interaction of lymphoid tissue inducer (LTi) cells and lymphoid tissue organizer (LTo) cells. The central role of the LTi cells in LN development is the expression and presentation of lymphotoxin alpha and beta (LTα1β2) to the LTβ receptor (LTβR) on LTo, and this interaction leads to organized lymphoid structures. The importance of this signal is demonstrated in mice deficient in LTβR or LTα, which lack LN and Peyer's patches (PP; De Togni et al., [@B29]; Futterer et al., [@B46]). Although the early differentiation pathway of LTi cells from multipotent hematopoietic progenitor cells remains to be characterized, studies suggest that the early specification to the LTi lineage takes place in lineage marker-negative (Lin^−^) populations, and α4β7 integrin, IL-7Rα^+^, and CD4^+^CD3^−^ are useful markers to define LTi (Mebius et al., [@B112]; Yoshida et al., [@B183]; Honda et al., [@B64]). A recent study shows that transcription factor Runx/Cbfb2 complexes are required for LTi cell differentiation (Tachibana et al., [@B160]). LTo cells, also called mesenchymal organizer cells or stromal organizer cell, express LTβR. LTo can be derived from the antimesenteric side of the intestine during development or from a hematopoietic cell lineage (Adachi et al., [@B1]; Nishikawa et al., [@B122]). The LTi--LTo interaction activates a signaling cascade resulting in the expression of adhesion molecules such as VCAM-1, intercellular cell adhesion molecule-1 (ICAM-1), and mucosal addressin cell adhesion molecule-1 and homeostatic chemokines such as CXCL13, CCL19, and CCL21 (van de Pavert and Mebius, [@B172]). CXCL13, the B zone chemokine, recruits circulating B cells to what becomes the B cell area; and the T zone chemokines, CCL19 and CCL21, attract T and DC to shape the T cell area (Cupedo and Mebius, [@B27]; Scandella et al., [@B141]). The human equivalent of murine LTi cells has been identified but has not been as well characterized as in mice. LTi cells in adult human are identified as IL-22 expressing NK type cells (Cupedo et al., [@B26]). The major phenotypic difference between mouse and human LTi cells is that mouse LTi cells are either CD4^+^ or CD4^−^, while human LTi cells are CD4^−^ or CD4^low^ (Kim et al., [@B80]).

In addition to organizing lymphoid structure during development, LTi cells are present in adult lymphoid tissues. Even after the maturation of SLO, a continuous interplay between lymphocytes and stromal cells is likely to be required for the maintenance of tissue architecture and the characteristics of adult stromal cells. Adult LTi cells express OX40L and CD30L, which are critical for memory CD4 T cell generation (Kim et al., [@B79]). OX40 and CD30 deficient mice have impaired CD4 T cell-dependent memory antibody responses in the spleen and gut (Lane et al., [@B89]; Tsuji et al., [@B170]). LTo give rise to various stromal cell subsets such as FDC and FRC that are present in lymphoid organs. However, it remains unknown how many different mesenchymal stromal cell types exist in SLO. The relationship between embryonic LTo cells and different types of stromal cells in adult SLO, and the postnatal fate of LTo cells are also unclear. It is possible that LTo-like cells persist in the adult and play a role in the maintenance of SLO. Katakai et al. ([@B76]) found a layer of unique reticular cells underneath the subcapsular sinus (SCS) lining of adult LNs. These specialized mesenchymal cells, marginal reticular cells (MRS), share many characteristics with LTo cells and are observed in mucosal SLO such as PP, nasal-associated lymphoid tissues, and isolated lymphoid follicles of adult mice (Katakai et al., [@B76]).

Splenic LTi-like cells contribute the development of SLO and also to host defense, by producing IL-17 and IL-22 in response to pathogen or IL-23 stimulation (Takatori et al., [@B162]). Phenotypically, splenic LTi-like cells in adult mice are similar to LN. They are CD4^+^CD3^−^NK1.1^−^CD11b^−^Gr-1^−^CD11c^−^B220^−^, express RORγt, aryl hydrocarbon receptor, IL-23R and CCR6, and are located mainly in the white pulp, particularly at the junction of T- and B-zones in the follicle. Formation of splenic white pulp does not require LTi cells, but the maturation of the tissue structure depends on LTα1β2 produced by lymphocytes and LTβR signaling (Fu and Chaplin, [@B44]), so that LTα, LTβ, or LTβR deficient mice display disrupted splenic architecture (De Togni et al., [@B29]). Thus, despite some similarities, the developmental program and molecular requirements of each SLO are clearly different.

Lymphotoxin system
------------------

LT is a tumor necrosis factor (TNF)-related cytokine required for the development and organization of SLO (Cyster, [@B28]). Its ligands and receptors are summarized in Figure [2](#F2){ref-type="fig"}. There are four closely related ligands: LTα; LTβ; TNF; and "homologous to LT, inducible expression, competes with herpes simplex virus (HSV) glycoprotein D for HSV entry mediator (HVEM), a receptor expressed on T lymphocytes" (LIGHT or TNFSF14). There are four cognate receptors: TNFR1; TNFR2; LTβ; and HVEM. LTα and LTβ form three different ligands, a secreted homotrimer LTα3 and two membrane-bound heterotrimers LTα1β2 (predominant form) and LTα2β1. The ligand--receptor binding patterns overlap within the family. LTα3 binds TNFR1 and TNFR2; LTα1β2 signals through LTβR; LTα2β1 binds TNFR1 and TNFR2; and LIGHT interacts with LTβR and HVEM. LTα3 may also bind HVEM (Schneider et al., [@B143]). As mentioned above, LT expressing LTi cells interact with the corresponding LTβR on the LTo cells during development. LTβR signaling is also required for maintaining the structure and regulating immune responses in adult mice (McCarthy et al., [@B111]).

![**The lymphotoxin receptors and their ligands**. The interactions of TNF cytokines with their cognate receptors are shown by arrows. Both LTα1/β2 and LIGHT bind to LTβR. HVEM binds to membrane or soluble LIGHT, soluble LTα3. Soluble LTα3 binds to TNFRI and TNFR II. Dashed line refers to weak interactions.](fimmu-02-00064-g002){#F2}

The development of the spleen is independent of LT, however, the microarchitecture of the splenic white pulp requires LTβR signaling for its development and maintenance in the adult mice. Treatment with LTβRIg, which blocks LT signaling, dissolves discrete B cell follicles, alters the marginal zone, prevents germinal center formation in the spleen, and impairs antibody production in response to immunization (Mackay et al., [@B106]).

Secondary lymphoid organs and tolerance
---------------------------------------

### Stromal cell function and tolerance

The appropriate structure of the SLO is integral in immune fate decisions, as following SLO entry naïve lymphocytes must decide to remain naïve, or become activated, anergic, or deleted. The presence (or absence) of antigen, co-stimulation, cell interactions, and/or chemokines/cytokines are all instructive in these decisions. Stromal cells construct intricate scaffolding within the SLO and provide architectural support. In addition to defining structure, these cells also contribute to lymphocyte trafficking, antigen presentation and cellular interactions (Mueller and Germain, [@B117]; Luther et al., [@B105]). FRC produce and secrete a fibrous antigen detected by the Erasmus University Rotterdam-thymic reticulum antibody 7 (ER-TR7; Steele et al., [@B154]) that forms a meshwork throughout the SLO (Van Vliet et al., [@B173]; Mueller and Germain, [@B117]). As elegantly demonstrated by Katakai et al. ([@B74]), the assembly of the ER-TR7 protein into this meshwork frame involves both FRC and lymphocyte collaboration and changes in response to antigen challenge, suggesting a structural plasticity that molds to the immune challenge at hand. To generate a fully formed meshwork, signaling through TNFR and LTβR via the inflammatory cytokines TNFα, LTα, and LTβ is required.

In the LN, lymphocytes leave the blood and enter via the HEV before flowing to the cortical ridge and cortical sinuses (Grigorova et al., [@B55]). As the HEV are the entry points for lymphocytes, the signals they present may be important factors in the genesis and shape of the immune response. Following inflammatory challenge, HEV express peripheral node addressin (PNAd), CCL21, ICAM-1, and CXCL9, attracting CD62L^+^, CCR7^+^, LFA-1^+^, and/or CXCR3^+^ T cells (Springer, [@B153]; Guarda et al., [@B56]). To attract B cells, HEV express CXCL13 resulting in cell arrest and LN entry (Kanemitsu et al., [@B72]). Even at this early phase of lymphocyte:LN interaction, lymphocytes encounter fate determining signals at the HEV. Activated T cells and antigen-presenting DC home to HEV following infection (Bajenoff et al., [@B10]), and we have shown both antigen and Treg seeding along HEV in tolerant mice following transplantation (Ochando et al., [@B124]). These findings suggest that these responding cells and/or antigen-presenting cells (APC) shape the migratory path of naïve lymphocytes into or through the LN and the subsequent immune response.

Following LN entry via HEV, or splenic entry via central arterioles in the marginal zone (Steiniger et al., [@B156]), lymphocytes encounter the FRC network, which dictates their path through the SLO (Mueller and Germain, [@B117]). The FRC are layered on top of and entwining the ER-TR7 scaffolding, forming a conduit system that transports molecules sampled from the lymph which has entered into the capsule and through the cortex (Katakai et al., [@B74]). Lymphocytes (Gretz et al., [@B52]), soluble factors (Gretz et al., [@B52]), low molecular mass molecules (Gretz et al., [@B53]), and antigen (Pape et al., [@B131]) pass through these conduits, traveling through the reticular network from the SCS to the HEV. Conduit-transported antigen travels to varying locations within the LN. If antigen is transported to follicles, B cells take it up and become activated (Pape et al., [@B131]). If the antigen is acquired from the lymph, it can be presented by lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1)^+^, conduit-associated, DC (Gretz et al., [@B52]). These resident DC are associated with reticular fibers within the LN (Sixt et al., [@B150]), and can take up antigen within minutes following exposure (Itano and Jenkins, [@B67]). Interestingly, immature DC (such as resident DC) adhere much more readily than mature DC (such as recently migrated inflammatory DC) to the extracellular matrix (Sixt et al., [@B150]), and may be of exceptional significance in terms of tolerance, as immature DC would fail to provide the requisite co-stimulation signals needed for T cell activation and may be tolerogenic (Itano and Jenkins, [@B67]). Hence, if potentially graft-reactive T cells encounter these immature as opposed to mature DC, the T cells may become anergic rather than primed.

Fibroblastic reticular cells not only form the physical structure of conduits to allow the flow of antigen and cells in the LN (Link et al., [@B97]) and spleen (Nolte et al., [@B123]), they also affect chemotaxis of lymphocytes and DC by producing chemokines and expressing adhesion markers. Stromal cells lining the HEV express CCL19 (Forster et al., [@B43]) and CCL21 (Luther et al., [@B104]; Forster et al., [@B43]), which are indispensable for attracting T cells and DC via surface CCR7 engagement, both to the LN and then to T cell area (Forster et al., [@B43]). Further, stromal cells express the adhesion molecules ICAM-1 (Boscacci et al., [@B17]), ICAM-2 (Boscacci et al., [@B17]), VCAM-1 (Katakai et al., [@B73]; Boscacci et al., [@B17]), and sialic acid (Kraal et al., [@B83]); adhesion molecules that direct lymphocytes expressing LFA-1 or α4β1 (Lo et al., [@B103]) to enter the HEV in the LN (Boscacci et al., [@B17]) or white pulp in the spleen (Kraal et al., [@B83]; Lo et al., [@B103]), and home to distinct microdomains.

The chemokines CXCL12 (Wright et al., [@B179]; Katakai et al., [@B73]) and CX3CL1 (Katakai et al., [@B73]) further direct lymphocyte homing to and within SLO (Boscacci et al., [@B17]). CXCL12, displayed on HEV (Okada et al., [@B127]), interacts with CXCR4 on central memory CD8^+^ T cells (Scimone et al., [@B144]) and B cells (Okada et al., [@B127]), attracting these cells to the LN independent of CCR7 expression (Scimone et al., [@B144]). CXCL12 expression may be of special importance in terms of transplant tolerance as it results in plasmacytoid DC (pDC) LN recruitment (Vanbervliet et al., [@B174]), and pDC presentation of donor antigen is integral to inducing tolerance to vascularized grafts (Ochando et al., [@B124]). Further, stromal cells guide activated follicular B cells to T cell zones and sites of T cell help following their upregulation of CCR7 (Reif et al., [@B139]).

Fibroblastic reticular cells may also deliver inhibitory or negative signals to lymphocytes, preventing their homing to and within SLO. FRC produce CCL2 (Katakai et al., [@B74]), resulting in decreased lymphocyte homing and effector function by preventing activation of LFA-1, inhibiting ICAM-1 attachment, and subsequent adhesion steps and travel to SLO (Flaishon et al., [@B39]). FRC also express class I MHC and the inhibitory molecule programmed cell death ligand 1 (PD-L1), and are thus capable of delivering signals to lymphocytes moving across their surfaces, influencing tolerance versus immune activation by tuning the responsiveness or activation state of the lymphocytes (Mueller and Ernst, [@B116]). Thus, FRC not only help attract lymphocytes to the LN and to specific areas within the LN, they also help dictate the interactions of the cells inside the LN. Interactions in the LN can also dictate where the activated lymphocytes travel following LN activation. By expressing retinoic acid in the LN, stromal cells (Hammerschmidt et al., [@B61]), and resident DC (Iwata et al., [@B68]) induce α4β7 and CCR9 upregulation of activated T cells, resulting in their travel to the gut.

Fibroblastic reticular cells provide both cues and scaffolding, dictating the movements, and interactions of the diverse cell populations residing and migrating through the SLO. These observations suggest a model in which a transplant recipient encounters donor antigen, and as the recipient responds to these antigens lymphoid organ structure is remodeled. SLO structure affects both primary and subsequent immune responses to alloantigens, altering where antigen is presented, which cell types encounter antigen, the activation signals detected by these cell types, and the interactions of the various cell populations. Further levels of complexity include that SLO structure is influenced by previous inflammatory and antigen challenges, so the structure within the SLO of the transplant recipient may be as unique as a fingerprint. Hence, detection of these distinctive structural and environmental pressures may provide novel and unique targets for designing therapeutic protocols.

### Spleen

The spleen's role in graft rejection is different between models such as vascularized or non-vascularized organ transplantation models. In some vascularized models, it contributes to graft rejection; however, in non-vascularized transplantation models, LN but not the spleen are essential for the rejection of skin allografts. Rather, the spleen appears to enhance graft prolongation (Souther et al., [@B152]; Streilein and Wiesner, [@B157]; Coons and Goldberg, [@B25]; Lakkis et al., [@B88]). The rejection of skin allografts depends on the presence of LN, whereas the rejection of vascularized heart allografts occurs in the presence of either the spleen or LN (Lakkis et al., [@B88]). On the contrary, Chosa et al. ([@B22]) showed that the spleen plays an important role in maintaining tolerance after removal of the vascularized heart graft. The APC migration route might explain the difference between models. In vascularized transplantation models, passenger leukocytes, including DC, are thought to migrate from the vascularized graft into the recipient spleen, where they activate T cells and cause rejection (Larsen et al., [@B90],[@B91]; Saiki et al., [@B140]). In the case of tolerance maintenance, naïve DC migrate to a tolerant graft and become regulatory or immature DC, these DC may then migrate to the spleen where they generate Treg (Chosa et al., [@B22]). CD4^+^ T cells from spleen of unresponsive cardiac allograft transplant recipients showed increased IL-10 and decreased IL-4 and IFNγ (DePaz et al., [@B30]).

In non-vascularized grafts, DC migrate from the graft to the regional draining LN. Activated DC are trapped in the LN where they generate effector T cells from naïve T cells. Regulatory or immature DC may pass through the LN, reach the spleen, and generate Treg. Several studies indicate that the expression pattern of chemokines and cytokine receptors between LN and spleen is different, explaining the different roles in transplant models (Tang and Cyster, [@B164]; Alferink et al., [@B3]).

Suppression and regulatory mechanisms of the spleen are shown in several studies. A subset of splenic red pulp F4/80^hi^Mac-1^low^ macrophages, whose differentiation is regulated by CSF-1, regulates CD4^+^ T cell responses using TGFβ and IL-10 and inducing differentiation of Foxp3^+^ Treg (Kurotaki et al., [@B87]). In a vascularized transplant model, Li et al. ([@B95]) showed that CD8^+^ Treg and pDC in the allograft and spleen induce tolerance. In mice, a rare cell type located in splenic red pulp with phenotypic attributes of DC (CD11c, CD8, CD80/86, MHCII) are uniquely competent to mediate T cell suppression via indoleamine oxidase after *in vivo* treatment with TLR9 ligands (Mellor et al., [@B113]; Johnson et al., [@B70]). NK cells have been shown to contribute to both graft rejection and tolerance both in cardiac and skin transplant models (Heidecke et al., [@B63]; Rabinovich et al., [@B137]; Beilke et al., [@B13]; Kroemer et al., [@B84]; Zecher et al., [@B184]). Thus, activated, regulatory, or immature DC and NK cells trapped in the spleen interact with other innate and adaptive immune cells, generate effector T cells and Treg, which contribute either to rejection or acceptance depending on the model (Murphy et al., [@B120]). The possibility that the spleen has the two functions of graft rejection and graft prolongation has been demonstrated in spleen transplantation models (Dor et al., [@B32]).

### Lymph node

In addition to dictating movement of lymphocytes within the LN by supplying both structure and directional cues, stromal cells may also dictate lymphocyte survival. Stromal cells affect T cell viability, and correct positioning within the LN is integral to T cell survival (Table [1](#T1){ref-type="table"}). Highlighting this importance is the effect of HIV pathogenesis on CD4^+^ T cell survival. Following HIV infection, the LN T cell zones become areas of significant pathology as viral replication occurs almost exclusively in these areas (Schacker et al., [@B142]). Innate immune cells attack these areas in attempts at viral eradication, resulting in scarring, and collagen deposition within LN niches (Estes et al., [@B37]), along with structural dissolution within the LN (Biberfeld et al., [@B16]). This scaring inhibits T cell access to FRC-produced IL-7, resulting in the depletion of T cells via apoptosis (Zeng et al., [@B186]). As T cells are depleted, the source of LTβ production is decreased, leading to further disruption of the FRC network (Zeng et al., [@B186]). The interdependence between FRC and T cells for the maintenance of LN structure demonstrates the balance among activation, ignorance, or tolerance that is dependent upon the microdomains within the LN structure.

###### 

**Stromal cells in SLO**.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                                Location                                          Phenotype                                                               Function                                                                                                                                                                                           
  ----------------------------------- ------------------------------------------------- ----------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --
  Follicular dendritic cell (FDC)     Cortex, B cell primary follicle (LN and spleen)   CD45^−^CD35^+^ FDC-M1^+^                                                Regulate B cell homeostasis, migration, and survival (Gunn et al., [@B57]; Hase et al., [@B62]; Munoz-Fernandez et al., [@B119])\                                                                  
                                                                                                                                                                Express complement and Fc receptors and are able to trap immune complexes to present B cells (Aguzzi and Krautler, [@B2])\                                                                         
                                                                                                                                                                Activate B cells by presenting exogenous antigen (El Shikh et al., [@B35])\                                                                                                                        
                                                                                                                                                                Express CXCL13, attracting naïve B cells expressing CXCR5 (Aguzzi and Krautler, [@B2])                                                                                                             

  Fibroblastic reticular cell (FRC)   Paracortex, T cell area (LN and spleen)           CD45^−^ gp38(podoplanin)^+^ CD31^−^ ER-TR7^+^ VCAM-1^high^ CD44^high^   Support B cell, T cell, and DC interactions (Katakai et al., [@B73]; Bajenoff et al., [@B9])\                                                                                                      
                                                                                                                                                                Directly induce tolerance of responding naïve CD8 T cells (Lee et al., [@B92])\                                                                                                                    
                                                                                                                                                                Express peripheral tissue antigens (PTAs)\                                                                                                                                                         
                                                                                                                                                                Present antigens to stimulate naïve T cells (Fletcher et al., [@B41])\                                                                                                                             
                                                                                                                                                                Secrete collagen and other extracellular matrix (Fletcher et al., [@B40])\                                                                                                                         
                                                                                                                                                                Create a conduit system of fine microchannels that conduct small lymph-borne antigens and inflammatory mediators deep into the LN paracortex B cells use the FRC network to reach the follicles\   
                                                                                                                                                                Express CCL19, CCL21, and SDF1 (CXCL12; Luther et al., [@B104])\                                                                                                                                   
                                                                                                                                                                Express IL-7 which promotes survival of naïve T cells (Link et al., [@B98])                                                                                                                        

  Lymphatic endothelial cell (LEC)    LN                                                CD45^−^ gp38^+^CD31^+^ VCAM-1^low^ CD44^low^                            Directly induce tolerance of responding naïve CD8 T cell (Cohen et al., [@B24]) Regulate T cell entry to and exit from LNs                                                                         

  Blood endothelial cell (BEC)        LN and spleen                                     CD45^−^gp38^−^ CD31^+^ VCAM-1^low^ CD44^low^                            Express PTAs (Cohen et al., [@B24]; Fletcher et al., [@B41]) Regulate T cell entry to and exit from LNs                                                                                            

  Double negative (DN)                                                                  CD45^−^gp38^−^CD31^−^                                                   Express PTAs (Cohen et al., [@B24]; Fletcher et al., [@B41])                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Stromal cells also participate in peripheral tolerance by expressing autoimmune regulator gene (*Aire*). *Aire* expression is most commonly associated with thymic expression of tissue-specific antigens; antigens that represent autologous proteins not typically present within the thymus. By presenting these antigens during thymic selection, potentially autoimmune T cells are deleted (Anderson et al., [@B4]). More recently, a role for *Aire* in peripheral tolerance has been demonstrated (Metzger and Anderson, [@B114]). Under steady-state conditions, tissue resident DC in the periphery pick up peripheral tissue-restricted antigen (PTA), and migrate to the LN (Waithman et al., [@B177]). There, *Aire*-expressing gp38^+^CD31^+^ lymphatic endothelial (Cohen et al., [@B24]) and gp38^+^CD31^−^ stromal cells (Gardner et al., [@B47]) express these antigens. These stromal cells express a variety of antigen processing and presentation genes, including MHC II, having phenotypic similarities to DC (Gardner et al., [@B47]). Hence, it is possible that allograft antigens, entering the LN either via lymphatic conduits or tissue DC, may be picked up by endothelial and/or stromal cells and presented to potentially graft-reactive lymphocytes, resulting in tolerance instead of activation. Indeed, the *Aire*-expressing stromal cells are preferentially located along boundaries of T and B cell interactions within the LN (Gardner et al., [@B47]), and are sufficient to drive both proliferation and deletion of self-reactive CD8^+^ T cells (Lee et al., [@B92]). Significantly, these stromal cells also express PD-L1, suggestive of a potential mechanism for peripheral cell deletion (Gardner et al., [@B47]). This CD8^+^ T cell deletion strategy is mirrored in chronic viral infection; LCMV upregulates PD-L1 in FRC, deleting virus-specific potential effector cells and allowing for viral persistence (Mueller et al., [@B118]).

Different subsets of stromal cells express *Aire* and PTA to varying degrees (Cohen et al., [@B24]). FRC express PTA under steady-state conditions, and down-modulate their antigen expression following an inflammatory stimulus (Fletcher et al., [@B40]). In contrast, other LN stromal cell subsets increase their PTA expression in response to bystander inflammation (Fletcher et al., [@B40]). Thus, specific subsets of stromal cells may be responsible for specific antigen tolerance. These findings may be exploited in transplant tolerance, as presentation of donor antigen in a non-inflammatory environment may engage several different tolerance mechanisms. Donor antigen could potentially be targeted to stromal cells for presentation, or therapeutic interventions may be able to exploit naturally occurring peripheral tolerance mechanisms.

Blood vascular endothelium
--------------------------

Dendritic cell and lymphocytes enter the LN through HEV and afferent lymphatics (von Andrian and Mempel, [@B176]). During this process, lymphatics and HEV not only play a role as a route for cell trafficking but also interact with the migrating immune cells to influence their immunologic properties and thereby immune responses. HEV are specialized postcapillary venules found in LN, where the lymphocytes circulating in the blood enter the LN by diapedesis (Girard and Springer, [@B49]). In order to facilitate the migration of lymphocytes, endothelial cells in HEV secrete CCL21, the CCR7 ligand, and express adhesion molecules such as PNAd (ligand for CD62L) and ICAM-1 (ligand for LFA-1; Campbell et al., [@B20]; Gunn et al., [@B58]; Forster et al., [@B43]). An additional chemokine CX3CL1, expressed on inflamed endothelial cells, interacts with its receptor CX3CR1 on activated cytotoxic lymphocytes, functioning as a cell adhesion molecule (Umehara et al., [@B171]). Another CCR7 ligand, CCL19, is produced by FRC in the T cell area and can be transported to the luminal surface of HEV to mediate T cell recruitment (Baekkevold et al., [@B8]; Link et al., [@B98]). CCR7 signaling is reported to induce cell cycle arrest in T cell receptor (TCR)-stimulated T cells and inhibit T cell proliferation (Ziegler et al., [@B189]). CCR7 signaling acts differently on DC. CCL19 and CCL21 induce DC to become mature; produce proinflammatory cytokines such as IL-1β, IL-12, and TNFα; and drive Th1 responses (Marsland et al., [@B109]). Thus, by engaging CCR7 and directing the migration of T cells and DC from blood into the LN, HEV induce significant changes in the maturation, differentiation, and responses of the migrating leukocytes.

Whether HEV enhance immune regulatory capacity of Treg is not certain. In an islet allograft model, adoptively transferred Treg that enter LN through HEV do not acquire an activated phenotype to suppress the alloimmune response (Zhang et al., [@B187]). On the other hand, activated endothelial cells from other sources such as thoracic aorta and lung induce and activate Treg using the PD-1/PD-L1 interaction and IL-10 (Krupnick et al., [@B85]; Bedke et al., [@B12]). Under inflammatory conditions, human endothelial cells amplify Treg in a contact-ICAM-1-dependent mechanism (Taflin et al., [@B161]). Under tolerogenic conditions, alloantigen-presenting pDC also migrate through HEV when homing to LN, to mediate Treg development and tolerance to vascularized cardiac allografts (Ochando et al., [@B124]).

Lymphatic endothelium
---------------------

Lymphatics are lined with LEC expressing LYVE-1. Lymphatics are found throughout the LN and have different functions and phenotypes in different regions. DC and T cells in peripheral tissues enter LN through afferent lymphatics, which typically end in the SCS, a hollow space below the fibrous capsule of the LN (Randolph et al., [@B138]). Thereafter, DC and T cells use different routes for entry into the LN parenchyma. By injecting cells directly into afferent lymph vessels, Braun et al. ([@B18]) showed that DC transmigrate through the floor of the SCS on the afferent side in CCR7-dependent fashion to enter the LN parenchyma. On the other hand, T cells enter the LN parenchyma mainly from peripheral medullary sinuses and this is not CCR7-dependent. However, CCR7 signals are absolutely required for the directional migration of both DC and T cells into the T cell zone. Interestingly, when DC are injected before T cells, T cells are able to transmigrate through the SCS floor. This suggests that DC transmigrating through the SCS induce changes in SCS morphology. In the steady state, Treg also enter the LN via afferent lymphatics, which is increased in inflammatory conditions (Tomura et al., [@B169]).

When leaving the LN, lymphocytes in the parenchyma enter medullary networks of lymphatic sinuses and from there the efferent lymphatics (von Andrian and Mempel, [@B176]). Lymphatics associated with the egress of lymphocytes are also found adjacent to HEV and B cell follicles in cortex (Sinha et al., [@B149]; Grigorova et al., [@B55]). These cortical sinuses extend to medullary sinuses. Emigration of lymphocytes into the efferent lymphatics for egress from the LN requires sphingosine-1-phosphate (S1P) interaction with the S1P receptor 1 (S1P~1~) on lymphocytes, and LEC are the main producers of S1P required for LN egress (Matloubian et al., [@B110]; Pham et al., [@B135]). In some immune responses and inflammatory conditions, lymphocytes down-regulate S1P~1~ expression, which blocks the egress of lymphocytes from the LN (Matloubian et al., [@B110]). Down-regulation of S1P~1~ by internalization is one of the major mechanisms of immune modulation by the drug FTY720 (Brinkmann et al., [@B19]).

Lymphatic vessels play an important role in immune tolerance. In an islet allograft model, Treg that are adoptively transferred and migrate from the graft to LN via afferent lymphatics prevent graft rejection. However, Treg which enter LN via HEV do not (Zhang et al., [@B187]). During a cutaneous immune response, Treg that move from skin to LN via afferent lymphatics are more potent in immune suppressive capacity than LN-resident Treg (Tomura et al., [@B169]). These findings suggest that migration through lymphatics may enhance the immunosuppressive capacity of Treg. Alternatively, it is possible that Treg are primed and activated in the peripheral tissues before migrating to LN. The chemokines CCL19 and CCL21, which are secreted by LEC, inhibit T cell proliferation (Ziegler et al., [@B189]). LN-resident LEC mediate peripheral tolerance by expressing and presenting multiple peripheral tissue antigens to CD8^+^ T cells and inducing their deletion (Cohen et al., [@B24]). Inflamed, TNFα-stimulated LEC reduce the expression of the co-stimulatory molecule CD86 by DC, and suppress the ability of DC to induce T cell proliferation via a Mac-1 (CD11b/CD18)/ICAM-1 (CD54)-dependent mechanism (Podgrabinska et al., [@B136]). Thus, LEC can engage multiple mechanisms to negatively regulate immune and inflammatory responses.

Vascular endothelial growth factors (VEGF), especially VEGF-A and VEGF-C, are involved in LEC proliferation and lymphangiogenesis (Shibuya and Claesson-Welsh, [@B145]; Tammela and Alitalo, [@B163]). Among VEGF receptors (VEGFR), VEGFR-2 is expressed both on blood vascular endothelium and lymphatic endothelium, but VEGFR-3 is specific for lymphatic endothelium. VEGF-A promotes lymphatic vessel formation via signaling through VEGFR-2 and the effect of VEGF-C is mediated by VEGFR-3. Chronic inflammatory conditions are associated with lymphangiogenesis in the draining LN, which enhances the migration of DC to LN and DC--T cell interactions. VEGF-C is induced in response to proinflammatory cytokines such as TNFα and IL-1β in several cells, including macrophages and granulocytes (Tammela and Alitalo, [@B163]). In inflammatory conditions, entry of these immune cells into the LN is markedly increased, which may be associated with inflammatory lymphangiogenesis in LN. B cells in inflamed LN produce VEGF-A and promote lymphangiogenesis (Angeli et al., [@B5]). Chronically inflamed tissue also induces lymphangiogenesis in draining LN by producing VEGF-A, and this is independent of B cells (Halin et al., [@B60]). On the other hand, T cells negatively regulate LN lymphatic vessel formation through IFNγ (Kataru et al., [@B77]). TGFβ also inhibits the proliferation and migration of cultured human LEC as well as lymphangiogenesis (Oka et al., [@B126]). Together, these reports suggest a highly complex network of tissue and LN interactions that regulate lymphangiogenesis.

In an islet allograft model, anti-VEGFR-3 mAb inhibits lymphangiogenesis and prolongs allograft survival, suggesting that inhibition of lymphangiogenesis may prevent immunity and inflammation (Yin et al., [@B182]). However, in an arthritis model of TNF-transgenic mice and a chronic cutaneous inflammation model, anti-VEGFR-3 mAb increases inflammation in joints and skin despite suppressing lymphangiogenesis (Guo et al., [@B59]; Huggenberger et al., [@B66]). In contrast to anti-VEGFR-3 mAb, anti-VEGFR-2 mAb suppresses both lymphangiogenesis and inflammation in these two models. It is suggested that VEGFR-2 and VEGFR-3 signaling pathways have different mechanisms for reducing lymphangiogenesis, and that increased inflammation after specific blockade of VEGFR-3 is a result of improper lymphatic drainage with failure to resolve inflammatory infiltrates.

Lymph node lymphatics and HEV seem to be in synchrony. B cell-derived VEGF-A promotes HEV expansion as well as lymphangiogenesis in LN (Shrestha et al., [@B148]). Both LN lymphatics and HEV express LTβR, and lymphangiogenesis is accompanied by upregulation of PNAd and LTβR by HEV, and is inhibited by LTβRIg treatment (Liao and Ruddle, [@B96]). These findings suggest that the two vascular systems engage in cross-talk through B cells and LTβR (Table [1](#T1){ref-type="table"}).

T cells
-------

When T cells enter LN through HEV or lymphatics, they are under the influence of chemokines secreted by LEC or vascular endothelial cells such as CCL19 and CCL21, which can inhibit the proliferation of T cells (Ziegler et al., [@B189]). Contact with endothelial cells also can affect the immunologic properties of migrating T cells. On the other hand, T cells can influence lymphatics and negatively regulate LN lymphatic vessel formation through IFNγ (Kataru et al., [@B77]).

T cell homing to LN plays a critical role in tolerance to alloantigen because Treg develop and are required within the LN during tolerance induction. If T cell homing to LN is inhibited by anti-L-selectin (CD62L) mAb, cardiac allograft survival is prevented despite a tolerogenic regimen of anti-CD40L mAb plus donor-specific transfusion (Ochando et al., [@B125]). Only the CD62L^+^ subpopulation of Treg, which have the LN-homing adhesion molecule, are reported to protect from lethal GVHD in allogeneic bone marrow transplantation model and delay adoptive transfer of diabetes (Szanya et al., [@B159]; Ermann et al., [@B36]). Follicular Treg are present in LN, limit T follicular helper cell and germinal center B cell numbers, and suppress germinal center reactions (Chung et al., [@B23]; Linterman et al., [@B99]). In LN, Treg directly interact with antigen-bearing DC by forming long-lasting conjugates to inhibit T cell priming and activation by DC (Tang et al., [@B165]). In the peripheral tissue, Treg inhibit DC migration to LN in a TGFβ and IL-10 dependent fashion, which prevents priming of effector T cells by DC in the LN (Zhang et al., [@B187]). These findings suggest that LN are a major place where Treg exert their immune modulatory actions in various ways. Treg limit the access of immune cells to LN and inhibit DC--T cell interactions in the LN for the regulation of immune reactivity (Table [2](#T2){ref-type="table"}).

###### 

**Treg in lymphoid organs**.

  -------------------------- ------------- --------------------------------- ---------------------------------------------------------------------------
  Primary lymphoid organ     Thymus        Treg development                  Involved cells:\
                                                                             Medullary epithelial cells expressing *Aire*, TSLP\
                                                                             Cortical DCs expressing TSLP\
                                                                             Recirculated immature DC\
                                                                             Involved molecules:\
                                                                             CD28, IL-2, TSLP, CD154, GITR, Stat5, TGFβ

                             Bone marrow   Treg recruitment                  CXCR4/CXCL12 interaction

                                           Treg role                         Providing immune-privileged sites for HSPC\
                                                                             Mobilized to peripheral tissue (i.e., tumor) via CCR4/CCL2 interaction

  Secondary lymphoid organ   Spleen        Treg generation                   Involved cells:\
                                                                             Regulatory or immature DC from peripheral tissues\
                                                                             F4/80^hi^Mac-1^low^ macrophages in red pulp

                             LN            Treg generation                   Involved cells:\
                                                                             DC migrated via afferent lymphatics\
                                                                             pDC migrated via HEV

                                           Treg role                         Treg migrated from peripheral tissues more potent than LN-resident Tregs\
                                                                             Inhibition of T cell priming and activation by Treg--DC interaction\
                                                                             Inhibition of T~FH~ cells/B cells/germinal center reaction by F~Treg~\
                                                                             Treg in peripheral tissues inhibit DCmigration to LN

  Tertiary lymphoid organ                  Treg detected; role not certain   
  -------------------------- ------------- --------------------------------- ---------------------------------------------------------------------------

Primary Lymphoid Organs
=======================

Thymus
------

The thymus is a lymphoid organ that is critical for tolerance. It is not only the site for eliminating self-reactive T cells through negative selection, but also for controlling self-reactive T cells through CD4^+^Foxp3^+^ regulatory T cell (Treg) development. Delayed generation of Treg by thymectomy at day 3, but not day 7, results in autoimmune disease development (Fontenot et al., [@B42]). Treg development is observed only when the antigen is expressed in the thymus (Jordan et al., [@B71]). Foxp3 is induced during very early thymic developmental events before TCR rearrangement (Pennington et al., [@B133]), suggesting a major role in determining T cell fate prior to or coincident with TCR engagement. These reports all demonstrate the critical role of the thymus for maintaining a protective suppressor cell population.

A number of observations show that Treg develop in the medulla: expression of *Aire* within medullary thymic epithelial cells (Aschenbrenner et al., [@B6]); the overwhelming majority of Foxp3^+^ cells are found within the medulla (Fontenot et al., [@B42]); and thymic stromal-derived lymphopoietin (TSLP) produced in the medullary region of the human thymus is critical for Treg development (Jiang et al., [@B69]). However, thymic DC also make TSLP and these cells may be found in the cortex (Watanabe et al., [@B178]); mice expressing MHC II only in the cortex are able to produce natural Treg (nTreg; Bensinger et al., [@B14]); and when thymic migration from the cortex to the medulla was blocked by administering pertussis toxin (Liston et al., [@B100]), or through CCR7 deficiency (Kurobe et al., [@B86]), CD4^+^Foxp3^+^ Treg accumulate within the cortex. Thus, both the thymic medulla and cortex participate in nTreg development. In a study using TCR transgenic models naturally devoid of Foxp3^+^ cells, it was observed that *de novo* generation of Treg occurred intrathymically under non-inflammatory conditions of antigen encounter and was essential for robust tolerance induction (Zelenay et al., [@B185]).

Foxp3 expression does not commence until day 3 in neonates, suggesting that only organized thymic architecture provides proper co-stimulatory signals in the early thymus. CD28, IL-2R, TSLP receptor, CD154, glucocorticoid-induced TNF receptor, and Stat5 signals are all implicated in the development and lineage commitment of thymus-derived nTreg (Bettini and Vignali, [@B15]). Although mice deficient in TGFβ or TGFβ receptor II (TGFβRII) have normal numbers of Treg in adult thymus, the numbers of CD4^+^CD25^+^Foxp3^+^ thymocytes are greatly reduced in young mice (Liu et al., [@B102]). Further, CD4^+^CD25^+^Foxp3^+^ thymocytes are completely lost in mice lacking both TGFβRI and IL-2, indicating TGFβR signaling is involved in development and maintenance of nTreg.

Various experimental models demonstrate that the thymus is required for Treg development and consequent tolerance induction to alloantigens. In a rat model using immature myeloid DC (imDC) primed with immune-dominant allopeptide *in vitro*, DC re-circulate through the recipient thymus and result in acquired graft-as-self-tolerance (Gopinathan et al., [@B50]; Oluwole et al., [@B129]). CD4^+^CD25^+^Foxp3^+^ anti-donor Treg development is dependent on the presence of the thymus for at least 2--3 weeks after imDC injection, and early thymectomy abolishes tolerance (Oluwole et al., [@B128]). Trafficking of donor alloantigen to the thymus or inoculating the thymus directly with allopeptides induces tolerance in large animal models, and thymectomy in recipients prevents tolerance induction (Griesemer et al., [@B54]). Transplanting porcine thymus tissue to mice leads to the development of donor-specific tolerance *in vitro* (Lee et al., [@B93]), and indefinite donor-matched porcine skin graft survival (Zhao et al., [@B188]). Transplanting vascularized porcine thymus tissue to baboons is associated with donor-specific T cell unresponsiveness (Barth et al., [@B11]), and the presence of thymic chimerism and donor bone marrow engraftment correlate precisely with tolerance to subsequent solid organ transplants (Horner et al., [@B65]). Overall, these reports demonstrate that both T cell development in allogeneic or xenogeneic thymus can induce tolerance, and that DC can traffic to the thymus to present or cross-present alloantigens for tolerance induction (Table [2](#T2){ref-type="table"}).

Bone marrow
-----------

Bone marrow is an essential part of the immature and mature lymphocyte recirculation network, and it harbors mature CD4^+^CD25^+^ Treg and serves as a Treg reservoir. Studies show that CXCR4/CXCL12 signals play an important role in regulating Treg trafficking from bone marrow and in maintaining homeostatic levels of Treg in the periphery. G-CSF treatment decreases bone marrow CXCL12 expression, and results in Treg mobilization from bone marrow into the periphery, and is consistent with the low prevalence of acute GVHD and the improvement in autoimmune diseases following G-CSF treatment (Zou et al., [@B190]). In a *ret* transgenic mouse spontaneous melanoma model, significantly higher numbers of Treg are found in skin tumors and metastatic LN at early stages of melanoma progression, compared with more advanced stages, and inversely correlate with Treg numbers in the bone marrow, suggesting trafficking from bone marrow to melanoma lesions. Elevated CCR4 expression is observed on Treg, while higher production of its ligand CCL2 is observed in tumor lesions, indicating CCR4/CCL2 signals play a role in Treg mobilization (Kimpfler et al., [@B81]). Recent studies show that the hematopoietic stem/progenitor cell (HSPC) niche is immune-privileged in the bone marrow. Persistence and survival of both allogeneic and syngeneic HSPCs are observed after 30 days in non-irradiated recipient mice without immunosuppression. High-resolution *in vivo* imaging shows that HSPC are colocalized with Treg and accumulate on the endosteal surface in the calvarial and trabecular bone marrow, Treg actively participate in protection of allo-HSPC, and depleting FoxP3 regulatory Treg cells results in allogeneic HSPC destruction (Fujisaki et al., [@B45]).

The bone marrow is the primary site for B cell maturation. Naive B cells then migrate to SLO, become plasmablasts upon antigenic stimulation in antigen-activated T cell areas, secrete low-affinity antibody and eventually undergo apoptosis. Some activated B cells enter into the long-lived memory compartment as either memory B cells or long-lived plasma cells (PC). Long-lived PC remain in either the LN or spleen, but most home to and reside in the bone marrow. Long-lived PC in the marrow are a major source of persistent donor-specific alloantibody (Stegall et al., [@B155]). Long-lived PC are sensitive to proteasome inhibition including bortezomib, but are not affected by rituximab, IVIG, or thymoglobulin (Perry et al., [@B134]). Although PC also may exist in SLO, the contribution of PC from areas other than the bone marrow to alloantibody production is not clear. These documentations all point to the bone marrow as a major site of immune regulation for responses to alloantigens, and that real therapeutic strategies must account for both Treg and PC in the bone marrow (Table [3](#T3){ref-type="table"}).

###### 

**Dendritic cell function in lymphoid organs**.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                      Subset                            Phenotype                                                       Location                                             Function                                                                                                                   
  ------------------------- --------------------------------- --------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lymphoid organ-resident   CD8^+^                            CD11c^+^CD11b^−^CD8^+^CD4^−^ (also CD103^+^CD207^+^ subset)     Spleen, LN and thymus                                Promote cytotoxic T cell responses                                                                                         CD8^+^ T cell tolerance Induce Treg\
                                                                                                                                                                                                                                                                                                              T cell suppression by IOD\
                                                                                                                                                                                                                                                                                                              CD4^+^ T cell hyporesponsiveness (Mellor et al., [@B113]; Dudziak et al., [@B34]; Yamazaki et al., [@B181]; Dominguez and Ardavin, [@B31]; Johnson et al., [@B70]; Shortman and Heath, [@B147])

                            CD4^+^                            CD11c^+^CD11b^+^CD8^−^CD4^+^                                    Spleen and LN                                        Promote CD4^+^ T cell responses                                                                                            CD4^+^ T cell tolerance\
                                                                                                                                                                                                                                                                                                              Expansion of Treg populations (Dudziak et al., [@B34]; Dominguez and Ardavin, [@B31]; Shortman and Heath, [@B147])

                            CD8^−^CD4^−^                      CD11c^+^CD8^−^CD4^−^ (CD11b^+^ and CD11b^−^ subsets)            Spleen and LN                                                                                                                                                                   

  Migratory                 CCR7^+^                           LC(CD11c^+^ CD207^+^CD103^−^)\                                  LN                                                   Transport the pathogen to the draining LN and promote T cell responses Up-regulate homing receptors of activated T cells   Carry PTA from periphery into LN CD8^+^ T cell tolerance\
                                                              CD103^+^CD11c^+^ (CD11b^+^CD103^+^)\                                                                                                                                                                                                            Induce Treg (Varol et al., [@B175]; Liu and Nussenzweig, [@B101])
                                                              CD103^+^CD11b^+^(CD11c^+^CD11b^−^CD103^+^)                                                                                                                                                                                                      

                                                              CD11b^+^? (CD11c^+^CD11b^+^CD103^−^)                            Not clear                                            Not clear                                                                                                                  Not clear

                            Plasmacytoid                      CD11c^mid^ CD11b^−^CD8^±^ CD4^+^Gr-1^+^ (produce type I IFNs)   Thymus, bone marrow, and secondary lymphoid tissue   Anti-viral immunity                                                                                                        Induce Tregs\
                                                                                                                                                                                                                                                                                                              Alloimmune tolerance (Ochando et al., [@B124]; Gilliet et al., [@B48]; Manches et al., [@B107]; Swiecki and Colonna, [@B158])

                            Inflammatory (TIP and monocyte)   CD11c^+^CD11b^+^Ly6C^+^ (produce TNF and express iNOS)          Inflammatory lesions                                 Induction of adaptive immunity                                                                                             Tezuka et al. ([@B166]), Kool et al. ([@B82]), Dominguez and Ardavin ([@B31])
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*"?" indicates that these cells may express CD11b*.

Tertiary Lymphoid Organs
========================

Ectopic or tertiary lymphoid organs (TLO) are often induced at sites of chronic infection or inflammation in peripheral non-lymphoid organs. These tissues are architecturally similar to SLO, with separate B and T cell areas, specialized populations of DC, well-differentiated stromal cells, and HEV (Carragher et al., [@B21]). It seems likely that similar signaling mechanisms that are responsible for SLO ontogeny are involved in TLO formation (Motallebzadeh et al., [@B115]). Like SLO, TLO are formed in a highly regulated manner via production of homeostatic chemokines (CXCL13 and CCL19/CCL21), and in response to signaling from the heterotrimer lymphotoxin (LT) α1β2 acting on the LTβR on stromal organizer cells (Drayton et al., [@B33]; van de Pavert and Mebius, [@B172]). The expression of LTα, LTβ, and LIGHT all contribute to the formation of TLO via signaling through TNFR1 and LTβR (Lee et al., [@B94]). Although the organogenesis of LN clearly requires LTi cells, whether LTi cells are required for formation of TLO follicles is less clear (Carragher et al., [@B21]). Even with deletion of the inhibitor of differentiation two gene, essential for generation of CD3^−^CD4^+^ LTi cells and development of SLO, TLO still form in the thyroid (Marinkovic et al., [@B108]).

Tertiary lymphoid organs have been described in a variety of autoimmune diseases including gastritis, thyroiditis, and systemic lupus erythematosus (Carragher et al., [@B21]). The formation of TLO correlates with the development of diabetes, whereas blocking their formation prevents the development of diabetes (Wu et al., [@B180]; Lee et al., [@B94]; Penaranda et al., [@B132]). The chronic phase of the immune response to an allograft is in many ways similar to the responses that typify relapsing autoimmunity. Autoimmune responses are characterized by immune environments in which target antigens persist, and the inability to eradicate alloantigens may provide a similar stimulus for formation of TLO within the graft. After organ transplantation, there are continuous low levels of dynamic interactions between donor alloantigens and the recipient immune system, a situation similar to chronic inflammation. The positioning of lymphoid tissue within an inflamed allograft may thus result in more aggressive effector lymphocyte responses that focuses on locally presented alloantigens (Motallebzadeh et al., [@B115]). For example, TLO or PNAd+ HEV without organized lymphoid accumulation are observed in murine heart transplants and in association with chronic allograft rejection, but to a much lesser extent with acute rejection (Baddoura et al., [@B7]). Germinal center-like structures are present in chronically rejected human allografts (Motallebzadeh et al., [@B115]). Some reports have shown that chronically rejected allografts are simultaneously the target and the site of production of alloantibodies (Smith et al., [@B151]; Kerjaschki et al., [@B78]; Thaunat et al., [@B167]; Thaunat and Nicoletti, [@B168]). TLO occur in rat donor allografts latently infected with cytomegalovirus (CMV), and in part mediate ganciclovir-insensitive rejection by providing a scaffold for immune activation (Orloff et al., [@B130]). Similarly, pre-transplant human CMV infection is associated with the acceleration of renal transplant vascular sclerosis and chronic allograft rejection (Fitzgerald et al., [@B38]). TLO within skin allografts are able to support effective alloresponses, leading to rejection, and development of a memory response (Nasr et al., [@B121]). Thus, it appears that the generation of TLO is associated with the chronic phase of destructive auto- or alloimmune responses.

The ectopic accumulation of lymphoid cells has been considered to signify destructive inflammation that is accompanied by tissue damage (Drayton et al., [@B33]). However, there are also examples in which TLO appear to contribute to local protective immune responses. A high proportion of Treg are detected within the TLO in gastric mucosa of mice with autoimmune gastritis and atherosclerotic aortic media of apoE^−^/^−^ mice (Katakai et al., [@B75]; Grabner et al., [@B51]). T2-6AB transgenic mice, in which T cells express a T cell receptor (TCR) specific for the H^+^/K^+^-ATPase α subunit, spontaneously develop TLO, although autoimmune responses are clearly limited. There is locally restricted T cell activation and Th2 skewing of the self-reactive T cells, as well as the accumulation of Treg in the target organ (Katakai et al., [@B75]). Many tumors manipulate the immune environment to escape immune surveillance. By secretion of CCL21, melanoma tumor cells attract LTi cells, which are needed for the formation of TLO-like structures within the tumor. Knockdown of endogenous CCL21 expression in tumor cells induces antigen-specific immunity and inhibits tumor growth. Hence, in melanoma tumors, the TLO provide a tolerogenic environment by recruitment of regulatory leukocyte populations (Shields et al., [@B146]). Thus, depending on the type of immune responses, generation of TLO at sites of inflammation can lead to detrimental or pathological immune responses, or may help resolve local inflammation or infection (Motallebzadeh et al., [@B115]).

Conclusion and Perspectives
===========================

While great progress has been made in understanding molecules, signaling pathways, and cells important for alloimmunity, and how to manipulate, interfere with, and suppress immune cell activation, migration, and effectors functions to benefit transplantation, evidence has emerged that various lymphoid organs, their anatomic structures, and particular microenvironments that lymphocytes encounter or reside in during the course of the alloresponse are also critical in determining the final outcome of graft acceptance and transplant tolerance. The appropriate tissue architecture may decide whether immune cells remain naïve, or become activated, anergic, or deleted by affecting antigen presentation, adhesion molecule expression, co-stimulatory signal activation, cytokine and chemokine production, thus affect regulatory and effector cell differentiation, trafficking and effector activities. In order to further overcome barriers to transplant tolerance, precise models and investigations on the arrangement of cells and molecules in lymphoid structures and anatomic pathways are required. For example, how LTi/LTo interactions, LT signal cascades, stromal cells, and specific microdomains affect immune responses and transplant tolerance induction and maintenance will all be productive areas for investigation.
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